88 results on '"DʼAvolio A"'
Search Results
2. Rebuttal letter: Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes
3. LC-MS/MS-Based Quantification of 9 Antiepileptic Drugs From a Dried Sample Spot Device
4. Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration–Time Curve of Linezolid for Different ABCB1 Genotypes
5. Shifting management in healthcare: An integrative review of design thinking
6. A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance
7. Clinical relevance of deferasirox trough levels in β‐thalassemia patients
8. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children
9. Cannabinoids concentration variability in cannabis olive oil galenic preparations
10. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma
11. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children
12. Treatment with direct‐acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study
13. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro‐resected patient
14. The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin‐induced anaemia in chronic hepatitis C Egyptian patients
15. Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients
16. Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?
17. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study
18. UPLC–MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells☆
19. UPLC–MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients
20. A LC–MS method to quantify tenofovir urinary concentrations in treated patients☆
21. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs
22. Pharmacokinetics of high dosage of linezolid in two morbidly obese patients
23. Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness
24. Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi
25. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir
26. In Vitro Stability Evaluation of Different Pharmaceutical Products Containing Meropenem
27. Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage
28. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon
29. An UPLC–MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells
30. Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots
31. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients
32. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
33. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E
34. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients
35. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug–drug interaction
36. Pharmacokinetics of the co-administration of boceprevir and St Johnʼs wort to male and female healthy volunteers
37. Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein
38. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection
39. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir
40. Development and validation of a useful UPLC–MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients☆
41. How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring?
42. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis
43. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa
44. Barriers to Primary Care: Perceptions of Older Adults Utilizing the ED for Nonurgent Visits
45. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy
46. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients
47. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
48. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes
49. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells
50. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.